OSE Immunotherapeutics’ Post

I would like to extend my congratulations to Professor El-Deiry and his colleague for their impressive paper. The potential impact of SARS-CoV-2 on cancer development and progression is a complex topic. Their study, along with other studies such as the previous one by Jafarzadeh et al., highlights the intricate interplay between SARS-CoV-2, the immune response, and cancer. This suggests that SARS-CoV-2 infection could potentially influence cancer outcomes. Jafarzadeh A, Gosain R, Mortazavi SMJ, Nemati M, Jafarzadeh S, Ghaderi A. SARS-CoV-2 Infection: A Possible Risk Factor for Incidence and Recurrence of Cancers. Int J Hematol Oncol Stem Cell Res. 2022 Apr 1;16(2):117-127. doi: 10.18502/ijhoscr.v16i2.9205. PMID: 36304732; PMCID: PMC9547773. https://lnkd.in/e8uEbeB7 Mortazavi, S. M. J., et al. (2023). "Should We Fear A Wave of Cancers After the COVID-19 Pandemic?" Journal of Biomedical Physics and Engineering. in press. https://lnkd.in/e-DsddXS Rubio-Casillas, A., et al. (2024). "Review: N1-methyl-pseudouridine (m1Ψ): Friend or foe of cancer?" International Journal of Biological Macromolecules 267: 131427.https://https://lnkd.in/exEc3PZj

How effective are RB-iDCs as a combined treatment for lung cancer? A new study from Journal of Immunology Research evaluates the immunological mechanism of RB-iDCs in a murine lung cancer model. Read the findings now ⬇️ #AOTY2022🏆

Spike protein and tumor suppressor p53:

“A number of cancer vaccines have recently entered clinical trials across the globe. These fall into two categories: personalised cancer immunotherapies, which rely on extracting a patient’s own genetic material from their tumours; and therapeutic cancer immunotherapies, such as the mRNA therapy newly launched in London, which are “ready made” and tailored to a particular type of cancer. The primary aim of the new trial – known as Mobilize – is to discover if this particular type of mRNA therapy is safe and tolerated by patients with lung or skin cancers and can shrink tumours. It will be administered alone in some cases and in combination with the existing cancer drug pembrolizumab in others.”- it is incredible to see any type of human trials conducted on cancer vaccines especially as the International Agency For Research on Cancer predicting that cancer rates will increase 77% by the middle of century (source: https://lnkd.in/gAgewZ_M). #cancervaccines #cancertreatment #cancerresearch #mrnavaccines #personalisedmedicine #solidcancers #interesting

🔬 Exciting Webinar Alert for Translational Oncology & Antibody Discovery Researchers! Are you delving into the complex interplay between immune responses and pancreatic ductal adenocarcinoma (PDAC)? This could be the breakthrough moment for your research! Join us for an enlightening webinar featuring Dr. Ming Yao, Sanders Tri-Institutional Therapeutics Discovery Institute, Inc. pioneering study on the immune microenvironment in PDAC and the role of B cell responses and Patrick Murphy, Ph.D., 10x Genomics discussing GEM-X the next generation of Single Cell profiling assays. #TranslationalOncology #AntibodyDiscovery #PDAC #Immunology #CancerResearch #Webinar

Check out this webinar from my former colleagues at JAX on novel mouse model selection to support preclinical research.

Exciting news in the fight against pancreatic cancer! A new experimental approach, building on groundbreaking research, is now entering the next phase, offering hope to patients worldwide. Results from a small study have paved the way for a phase 2 clinical trial to evaluate the efficacy of an mRNA vaccine in combating pancreatic cancer. The trial, involving approximately 260 patients at Memorial Sloan Kettering Cancer Center and 80 global sites, focuses on reducing the risk of cancer recurrence post-surgery. Custom-made mRNA vaccines, unique to each patient, utilize proteins (neoantigens) in pancreatic tumors to signal the immune system and train it to recognize and fight cancer cells. The phase 1 trial, reported in Nature on May 10, 2023, demonstrated the safety and potential benefits of the mRNA vaccines. Join us in supporting this promising journey towards improved outcomes and a brighter future for patients. #PancreaticCancerResearch #MedicalAdvancements #mRNAVaccineHope #cancervaccine #cancerimmunotherapy #breakthrough

Glycosylphosphatidylinositol anchor biosynthesis pathway-based biomarker identification with machine learning for prognosis and T cell exhaustion status prediction in breast cancer Frontiers https://lnkd.in/gE24kTXD

New mRNA Vaccine May Prevent Pancreatic Cancer Recurrence: Unlike traditional vaccines, which are one-size-fits-all, mRNA vaccines are tailored to each individual, with the aim of stimulating the production of specific immune cells known as T cells. These T cells are trained to recognize and target pancreatic cancer cells, reducing the risk of cancer recurrence following surgical removal of the primary tumor. Among the 16 patients studied, eight experienced activation of T cells that recognized their own pancreatic cancers. Importantly, these patients demonstrated delayed recurrence of their pancreatic cancers, providing tantalizing evidence that the T cells activated by the vaccines may be effectively holding the cancer at bay. #cancer #oncology #pancreaticcancer #drugdiscovery #mrna #immunotherapy #vaccine #health #drugdevelopment #drugdelivery #pharmaceuticalindustry BioNTech SE Moderna Vinod Balachandran